Keyphrases
Clinical Trials
74%
Olaparib
47%
Risk-benefit
32%
Cancer Clinical Trials
29%
Objective Response Rate
26%
Reporting Guidelines
23%
Risk Outcomes
23%
Patient Outcomes
23%
Urology
23%
Selinexor
23%
Solid Malignancies
23%
Patient Benefit
23%
Drug Development
23%
Patient Risk
23%
Trialists
23%
Prostate Cancer
23%
Web-based Survey
23%
Clinical Perspective
23%
Core Outcome Set
23%
Clinical Trial Registry
20%
Adverse Events
17%
Overall Survival
17%
Progression-free Survival
14%
Control Arm
14%
New Indication
11%
Drug Manufacturer
11%
Ovarian Cancer
11%
Instructions to Authors
10%
Trial Characteristics
8%
PubMed
8%
Median Progression-free Survival
8%
Cochrane
8%
Embase
8%
MEDLINE
8%
Descriptive Statistics
8%
Health Research
6%
Capital Investment
5%
Time Investment
5%
Pooled Analysis
5%
Mutation Characteristics
5%
Therapy Options
5%
Safety Criteria
5%
Novel Chemotherapy
5%
Drug Efficacy
5%
Trial Reporting
5%
Adverse Event Rates
5%
Oncologic
5%
Solid Cancer
5%
Oncology
5%
Complete Response
5%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Olaparib
47%
Cross Sectional Study
23%
Drug Development
23%
Selinexor
23%
Prostate Cancer
23%
Adverse Event
23%
Progression Free Survival
23%
Malignant Neoplasm
20%
Overall Survival
17%
Ovary Cancer
11%
Pharmaceutical Manufacturing
11%
Multiple Myeloma
5%
Chemotherapy
5%
Solid Malignant Neoplasm
5%
Medicine and Dentistry
Clinical Trial
72%
Olaparib
47%
Prostate Cancer
23%
Cross Sectional Study
23%
Urology
23%
Malignant Neoplasm
20%
Ovarian Cancer
11%
Adverse Event
11%
Progression Free Survival
11%
Pooled Analysis
5%
Drug Therapy
5%
Oncology
5%
Drug Efficacy
5%
Clinician
5%
Overall Survival
5%
Lifespan
5%
Solid Malignant Neoplasm
5%
